Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient neuroprotection against ischemic stroke

Guolong Yu, David C. Hess, Cesario V. Borlongan

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

We investigated the neuroprotective effects of immunosuppressant cyclosporine-A (CsA) and the anti-inflammatory methylprednisolone (MP) in a stroke model. Adult Sprague-Dawley rats underwent middle cerebral artery (MCA) occlusion then were randomly treated with either: low dose CsA, MP, low dose CsA plus MP, high dose CsA, or vehicle. Ischemic animals that received low dose CsA, MP or vehicle displayed profound motor and neurological impairments at days 1-3 after stroke. In contrast, ischemic animals that received high dose CsA exhibited near normal motor and neurological functions throughout the test period. Of note, ischemic animals that received low dose CsA plus MP showed significantly less motor and neurological deficits at day 1, but thereafter displayed behavioral impairments. Histological analysis at 3 days post-stroke revealed that only those ischemic animals treated with high dose CsA had significantly reduced cerebral infarcts. This study is the first report to demonstrate partial and transient neuroprotection against stroke by low dose CsA when combined with MP.

Original languageEnglish (US)
Pages (from-to)32-37
Number of pages6
JournalBrain Research
Volume1018
Issue number1
DOIs
StatePublished - Aug 20 2004
Externally publishedYes

Keywords

  • Animal model
  • Brain infarct
  • Cerebral ischemia
  • Disorders of the CNS
  • Functional recovery
  • Immunosuppression
  • Inflammation
  • Ischemia
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Fingerprint Dive into the research topics of 'Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient neuroprotection against ischemic stroke'. Together they form a unique fingerprint.

  • Cite this